deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT03066258

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Sponsor: REGENXBIO Inc.

Conditions Neovascular Age-related Macular Degeneration Wet Age-related Macular Degeneration
Interventions RGX-314
Updated 16 times since 2017 Last updated: May 12, 2023 Started: Mar 29, 2017 Primary completion: Nov 24, 2019 Completion: Jun 17, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Neovascular Age-related Macular Degeneration and Wet Age-related Macular Degeneration and is currently completed. REGENXBIO Inc. leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Dec 2017 · 7 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Mar 2019 · 6 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Jan 2020 · 7 months · monthly snapshot~Jan 2020 – ~Nov 2020 · 10 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2022 · 16 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jun 2023 · 7 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  4. Nov 2022 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 11 earlier versions

  1. May 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Jun 2019 — Jan 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  7. Sep 2018 — Mar 2019 [monthly]

    Recruiting PHASE1

  8. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  9. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  10. May 2017 — Dec 2017 [monthly]

    Recruiting PHASE1

  11. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • REGENXBIO Inc.
Data source: REGENXBIO Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations